Match tier
Listed
Presence
Current · Arkansas
Last published
2025
Sources
OpenAlex · ORCID
Refreshed
2026-10-05
P
Peter Dean Emanuel
Federal Grant PI
High Impact
Professor
Also affiliated: University of Southern California (1998); Atrium Health Wake Forest Baptist (1998); National Institutes of Health (1998); Memorial Sloan Kettering Cancer Center (2000); Children's Hospital of Los Angeles (1998); Johns Hopkins University (2002); The University of Texas at San Antonio Health Science Center (2002); Duke University (2002); University of California, San Francisco (1998–2006); University of Oslo (2002); Sanford Burnham Prebys Medical Discovery Institute (1998); University of Washington (2006); University of South Florida (1994); University of Arkansas Medical Center (2008–2018); Moffitt Cancer Center (1994); University of Alabama at Birmingham (1990–2009); University of Chicago (2006); Birmingham VA Medical Center (2002); Duke Medical Center (2002); Children's Hospital of Pittsburgh (1997); Children's Oncology Group (2005–2007); St. John Hospital & Medical Center (2002); Stanford Medicine (2020); National Cancer Institute (1998); South Texas Veterans Health Care System (2002); UCSF Helen Diller Family Comprehensive Cancer Center (2006); Wake Forest Baptist Comprehensive Cancer Center (1998); UAB Medicine (1990–2006); Wake Forest University (1998); Stanford University (2020)
32 h-index
107 pubs
3,602 cited
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Peter D. Emanuel studies pediatric myeloid neoplasms, focusing on their genomic landscape and clonal architecture. His research investigates juvenile myelomonocytic leukemia, examining the sensitivity of its stem cells to natural killer (NK) cell-mediated lysis and identifying targetable antigens. Emanuel also explores potential therapeutic targets for myeloid proliferation neoplasia, including investigations into MLN0128 as a treatment that may prolong survival.
Emanuel is a principal investigator on a federal grant from the NIH/National Institute of General Medical Sciences for the acquisition of a NovaSeq X Plus Advanced Next Generation Sequencer. This instrument supports his work in genomics and related areas.
His scholarship metrics include an h-index of 32, with 108 total publications and 3,565 total citations. He is recognized as a high-impact researcher, indicated by his high citation count. Emanuel collaborates with Y. Lucy Liu at the University of Arkansas for Medical Sciences, with whom he has co-authored two publications.
Metrics
- h-index: 32
- Publications: 107
- Citations: 3,602
Positions
-
Professor 2007–presentUniversity of Arkansas for Medical Sciences Medicine ORCID
-
Professor 1991–2007University of Alabama at Birmingham Medicine ORCID
Selected Publications
-
Juvenile myelomonocytic leukemia stem cells are sensitive to NK cell–mediated lysis and express targetable antigens (2025)
-
Sustained fetal hematopoiesis causes juvenile death from leukemia: evidence from a dual-age–specific mouse model (2020)
-
PTEN is indispensable for cells to respond to MAPK inhibitors in myeloid leukemia (2018)
-
Unleashing natural killer cells upon immunization with a carbohydrate mimetic peptide vaccine. (2018)
-
Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects (2017)
-
Managing Expectations in the Transition to Proof of Concept Studies (2017)
-
Fludarabine, Melphalan, and Alemtuzumab Conditioning Regimen in High Risk Leukemia: The Arkansas Experience (2017)
-
The Dosage of Pten Is Critical in Determining the Disease Severity - a Mouse Model Differentially Mimicking JMML and CMML (2016)
-
Patterns of Incidence and Survival of Therapy Related Myeloid Neoplasms in United States (2016)
-
JQ1, a Potential Therapeutic Molecule for Myeloid Leukemia with PTEN Deficiency (2016)
-
A rare case of blastic plasmacytoid dendritic cell neoplasm with deletion 7q.31, in the setting of heavy pre-treatment with alkylating chemotherapy (2016)
-
Incidence and survival of chronic myelomonocytic leukemia (CMML) in the United States (US). (2015)
-
Outcomes of primary plasmacytoma (PP) in United States (US). (2015)
-
Overall Outcomes of Bing-Neel Syndrome after Treatment - a Review of 40 Cases (2015)
-
MYC amplification in multiple marker chromosomes and EZH2 microdeletion in a man with acute myeloid leukemia (2015)
Federal Grants 1 $750,000 total
NIH
Contact PI
Jun 2024 - Jun 2025
Collaboration Network
Top Collaborators
Y. Lucy Liu
Winthrop Rockefeller Foundation
20 shared publications
In database
- The genomic landscape of juvenile myelomonocytic leukemia
- Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia
- Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: A report from the Children's Oncology Group
- PTEN deficiency is a common defect in juvenile myelomonocytic leukemia
- Mutations in GATA2 are rare in juvenile myelomonocytic leukemia
Showing 5 of 20 shared publications
Mignon L. Loh
University of California, San Francisco (US)
7 shared publications
- Mutations in CBL occur frequently in juvenile myelomonocytic leukemia
- Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia
- Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: A report from the Children's Oncology Group
- Deficiency of CREB and over expression of miR-183 in juvenile myelomonocytic leukemia
- Mutations in GATA2 are rare in juvenile myelomonocytic leukemia
Showing 5 of 7 shared publications
Shelly Lensing
University of Arkansas for Medical Sciences (US)
7 shared publications
- Deficiency of CREB and over expression of miR-183 in juvenile myelomonocytic leukemia
- Sustained fetal hematopoiesis causes juvenile death from leukemia: evidence from a dual-age–specific mouse model
- JQ1, a Potential Therapeutic Molecule for Myeloid Leukemia with PTEN Deficiency
- Overexpression Of DNMT3a and DNMT3b Is Related To Downregulation Of Mir-29a In Juvenile Myelomonocytic Leukemia (JMML)
- Timing of the Loss of Pten Is Critical in Determining the Disease Phenotype in Mice- a Mouse Model for Pediatric Mixed MDS/MPN
Showing 5 of 7 shared publications
Elliot Stieglitz
UCSF Benioff Children's Hospital (US)
7 shared publications
- The genomic landscape of juvenile myelomonocytic leukemia
- Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia
- Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: A report from the Children's Oncology Group
- Mutations in GATA2 are rare in juvenile myelomonocytic leukemia
- Subclonal Mutations in SETBP1 Predict Relapse in Juvenile Myelomonocytic Leukemia
Showing 5 of 7 shared publications
Robert P. Castleberry
Children's of Alabama (US)
6 shared publications
- Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: A report from the Children's Oncology Group
- PTEN deficiency is a common defect in juvenile myelomonocytic leukemia
- Mutations in GATA2 are rare in juvenile myelomonocytic leukemia
- Author's response to the comments on “PTEN deficiency is a common defect in juvenile myelomonocytic leukemia” [Leuk. Res. (2008) (Epub November 17)]
- CREB Deficiency: A Potential Critical Factor for Selective GM-CSF Hypersensitivity in Juvenile Myelomonocytic Leukemia.
Showing 5 of 6 shared publications
Yan Yan
University of Arkansas for Medical Sciences (US)
6 shared publications
- PTEN is indispensable for cells to respond to MAPK inhibitors in myeloid leukemia
- Sustained fetal hematopoiesis causes juvenile death from leukemia: evidence from a dual-age–specific mouse model
- JQ1, a Potential Therapeutic Molecule for Myeloid Leukemia with PTEN Deficiency
- Overexpression Of DNMT3a and DNMT3b Is Related To Downregulation Of Mir-29a In Juvenile Myelomonocytic Leukemia (JMML)
- Timing of the Loss of Pten Is Critical in Determining the Disease Phenotype in Mice- a Mouse Model for Pediatric Mixed MDS/MPN
Showing 5 of 6 shared publications
Issam Makhoul
University of Arkansas for Medical Sciences
6 shared publications
In database
- Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects
- Moving a Carbohydrate Mimetic Peptide into the clinic
- Overall Outcomes of Bing-Neel Syndrome after Treatment - a Review of 40 Cases
- Managing Expectations in the Transition to Proof of Concept Studies
- Unleashing natural killer cells upon immunization with a carbohydrate mimetic peptide vaccine.
Showing 5 of 6 shared publications
Laura F. Hutchins
University of Arkansas for Medical Sciences
6 shared publications
In database
- Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects
- Moving a Carbohydrate Mimetic Peptide into the clinic
- Managing Expectations in the Transition to Proof of Concept Studies
- Unleashing natural killer cells upon immunization with a carbohydrate mimetic peptide vaccine.
- Survival outcomes of primary myelodysplastic syndrome in United States.
Showing 5 of 6 shared publications
Yogesh Jethava
University of Arkansas for Medical Sciences (US)
6 shared publications
- A rare case of blastic plasmacytoid dendritic cell neoplasm with deletion 7q.31, in the setting of heavy pre-treatment with alkylating chemotherapy
- Outcomes of primary plasmacytoma (PP) in United States (US).
- Fludarabine, Melphalan, and Alemtuzumab Conditioning Regimen in High Risk Leukemia: The Arkansas Experience
- Incidence and survival of chronic myelomonocytic leukemia (CMML) in the United States (US).
- Survival outcomes of primary myelodysplastic syndrome in United States.
Showing 5 of 6 shared publications
Zhifu Xiang
University of Arkansas for Medical Sciences (US)
5 shared publications
- PTEN is indispensable for cells to respond to MAPK inhibitors in myeloid leukemia
- MYC amplification in multiple marker chromosomes and EZH2 microdeletion in a man with acute myeloid leukemia
- Overall Outcomes of Bing-Neel Syndrome after Treatment - a Review of 40 Cases
- Timing of the Loss of Pten Is Critical in Determining the Disease Phenotype in Mice- a Mouse Model for Pediatric Mixed MDS/MPN
- Natural history of chronic myelomonocytic leukemia: gene sequencing identifies multiple clonal molecular abnormalities associated with rapid progression to acute myeloid leukemia
Todd M. Cooper
Children's Healthcare of Atlanta (US)
5 shared publications
- The genomic landscape of juvenile myelomonocytic leukemia
- Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: A report from the Children's Oncology Group
- Deficiency of CREB and over expression of miR-183 in juvenile myelomonocytic leukemia
- Mutations in GATA2 are rare in juvenile myelomonocytic leukemia
- Mutations In GATA2 Are Rare In Juvenile Myelomonocytic Leukemia
Paulette Mehta
Central Arkansas Veterans Healthcare System
4 shared publications
In database
- MYC amplification in multiple marker chromosomes and EZH2 microdeletion in a man with acute myeloid leukemia
- Natural history of chronic myelomonocytic leukemia: gene sequencing identifies multiple clonal molecular abnormalities associated with rapid progression to acute myeloid leukemia
- Outcomes of primary plasmacytoma (PP) in United States (US).
- Incidence and survival of chronic myelomonocytic leukemia (CMML) in the United States (US).
Priyangi A. Malaviarachchi
Winthrop Rockefeller Foundation
4 shared publications
In database
- PTEN transcript variants caused by illegitimate splicing in “aged” blood samples and EBV-transformed cell lines
- PTEN is indispensable for cells to respond to MAPK inhibitors in myeloid leukemia
- CREB Deficiency: A Potential Critical Factor for Selective GM-CSF Hypersensitivity in Juvenile Myelomonocytic Leukemia.
- Restoring Cell Responsiveness to GM-CSF and IL-3 by PTEN Is Via Controlling the Regulation of Egr-1 In TF-1a Cell Line
Angela Pennisi
University of Arkansas for Medical Sciences (US)
4 shared publications
- Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects
- Moving a Carbohydrate Mimetic Peptide into the clinic
- Managing Expectations in the Transition to Proof of Concept Studies
- Unleashing natural killer cells upon immunization with a carbohydrate mimetic peptide vaccine.
Eric R. Siegel
University of Arkansas for Medical Sciences
4 shared publications
In database
- Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects
- Moving a Carbohydrate Mimetic Peptide into the clinic
- Managing Expectations in the Transition to Proof of Concept Studies
- Unleashing natural killer cells upon immunization with a carbohydrate mimetic peptide vaccine.
Similar Researchers
Based on overlapping research topics
Y. Lucy Liu
University of Arkansas for Medical Sciences
Genomics and Phylogenetic Studies
Child and Adolescent Health
Cancer-related molecular mechanisms research
Jacob L Edmondson
University of Arkansas for Medical Sciences
Genomics and Phylogenetic Studies
Cancer-related molecular mechanisms research
Metabolism and Genetic Disorders
Jason E. Farrar
University of Arkansas for Medical Sciences
Genomics and Phylogenetic Studies
Child and Adolescent Health
Cancer-related molecular mechanisms research
Ahmad Mazin Safar
University of Arkansas for Medical Sciences
Genomics and Phylogenetic Studies
Cancer-related molecular mechanisms research
Molecular Biology Techniques and Applications
Supriya Jambhekar
University of Arkansas for Medical Sciences
Genomics and Phylogenetic Studies
Child and Adolescent Health
Metabolism and Genetic Disorders
Christophe Bobda
University of Arkansas for Medical Sciences
Genomics and Phylogenetic Studies
Cancer-related molecular mechanisms research
Metabolism and Genetic Disorders